Yükleniyor... / Loading...
This study observes treatment pathways and the use of molecular testing in patients with newly diagnosed non-small cell lung cancer (NSCLC). It enrolls patients aged 18 and older with early-stage, locally advanced or metastatic disease who are eligible for systemic therapy. It is a study without an assigned phase and is currently active but not recruiting participants.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancer * Eligible for systemic therapy based on the treating provider's assessment * Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease * Subjects may be enrolled within 30 days of initiation of systemic therapy * Signed informed consent Exclusion Criteria: * Stage IA at the time of enrollment * Subjects with small cell lung cancer * Subjects with Unknown primary tumor origin